<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>Antineoplastic drugs : organic syntheses</title>
  </titleInfo>
  <name type="personal">
    <namePart>Lednicer, Daniel</namePart>
    <namePart type="date">1929-</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <typeOfResource>text</typeOfResource>
  <genre authority="marc">bibliography</genre>
  <genre authority="">Electronic books.</genre>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">enk</placeTerm>
    </place>
    <dateIssued encoding="marc">2015</dateIssued>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <form authority="gmd">electronic resource</form>
    <extent>1 online resource.</extent>
  </physicalDescription>
  <abstract>"Antineoplastic Drugs: Organic Syntheses is written to appeal to organic and medicinal chemists in industry and academia. It is beneficial to those composing grant proposals for NCI and related organizations"--</abstract>
  <tableOfContents>Title Page; Copyright Page; Contents; Preface; Introduction; Chapter 1 Alkylating Agents; 1.1 bis-Chloroethyl Amines; 1.2 Several Other Chloroethyl Agents; 1.3 Platinum-Based Antineoplastic Agents; 1.4 Miscellaneous Alkylating Agents; References; Chapter 2 Antimetabolites; 2.1 Introduction; 2.2 Folate Antagonists; 2.2.1 Compounds with Glutamate Side Chain; 2.2.2 Compounds Lacking the Glutamate Moiety; 2.2.3 Methoxylated Benzenes; 2.3 Pyrimidines and Purines; 2.3.1 Aglycones; 2.3.2 Saccharide-Linked Compounds; References; Chapter 3 Hormone Blocking Anticancer Drugs; 3.1 Introduction.</tableOfContents>
  <tableOfContents>3.2 Estrogen Antagonists3.2.1 Estrogen Antagonists; 3.2.2 Aromatase Inhibitors; 3.3 Androgen Antagonists; 3.3.1 Non-steroidal Antian drogens; 3.3.2 Steroid Androgen Antagonists; References; Chapter 4 Topoisomerase Inhibitors; 4.1 Introduction; 4.2 Anthracyclines; 4.3 Anthraquinones and Anthrapyrazoles; 4.3.1 Anthraquinones with Two Aminoalkyl Side Chains; 4.3.2 Anthraquinones with a Fused Pyrazole Ring; 4.3.3 Heterocyclic Anthraquinones; 4.4 Camptothecins; 4.4.1 Compounds from Modified Camptothecin; 4.4.2 Camptothecins by Total Synthesis; 4.5 Miscellaneous Topoisomerase Inhibitors; References.</tableOfContents>
  <tableOfContents>Chapter 5 Mitotic Inhibitors5.1 Introduction; 5.2 Taxanes; 5.3 Wholly Synthetic Compounds; 5.3.1 Carbocyclic Compounds; 5.3.2 Peptide-Like Inhibitors; 5.3.3 Monocyclic Heterocyclic Inhibitors; 5.3.4 Bicyclic 5:6 Heterocyclic Inhibitors; 5.3.5 Bicyclic 6:6 Heterocyclic Tubulin Inhibitors; References; Chapter 6 Matrix Metalloproteinase Inhibitors; 6.1 Introduction; 6.2 Hydroxamates; 6.2.1 Agents with an Isobutyl Moiety; 6.2.2 A Thiomorpholine; 6.2.3 Sulfamates; 6.2.4 Miscellaneous Compounds; References; Chapter 7 Histone Deacetylase Inhibitors; 7.1 Introduction; 7.2 Hydroxamates.</tableOfContents>
  <tableOfContents>7.3 PhenylenediaminesReferences; Chapter 8 Enzyme Inhibitor, Part I, Tyrosine Kinases; 8.1 Introduction; 8.2 Epidermal Growth Factor Inhibitors; 8.3 VEGF; 8.3.1 Fused Ring Compounds; 8.3.2 Linear Arrays; 8.4 SRC Nonreceptor Tyrosine Kinase; 8.5 PDGF; 8.6 EGF; 8.7 Other TKI; 8.7.1 Linear Arrays; 8.7.2 Compounds with Two Fused Rings; 8.8 Janus Kinase Inhibitors; References; Chapter 9 Enzyme Inhibitors: Part II Additional Targets; 9.1 Serine-Threonine Kinase Inhibitors; 9.2 Additional Enzyme Inhibitors; 9.2.1 Farnesyl Transferase Inhibitors; 9.2.2 Cyclin-Dependent Kinase Inhibitors.</tableOfContents>
  <tableOfContents>9.2.3 Proteasome Inhibitors9.2.4 PARP Inhibitors; 9.2.5 Various Other Enzyme Inhibitors; References; Chapter 10 Miscellaneous Antineoplastic Agents; 10.1 Acyclic; 10.2 Monocyclic; 10.3 Two Linked Rings; 10.4 Rings on a Chain; 10.4.1 Two Rings; 10.4.2 Four and More Rings; 10.5 Fused Rings; 10.5.1 Indoles; 10.5.2 Purine-Like; 10.5.3 Tetralins and a Naphthalene; 10.5.4 Etc.; References; Appendix A; Index of Heterocycle Syntheses; Subject Index; EULA.</tableOfContents>
  <note type="statement of responsibility">Daniel Lednicer.</note>
  <note>Includes bibliographical references and index.</note>
  <subject authority="lcsh">
    <topic>Antineoplastic agents</topic>
  </subject>
  <subject authority="lcsh">
    <topic>Drugs</topic>
    <topic>Synthesis</topic>
  </subject>
  <subject>
    <topic>Antimetabolites</topic>
  </subject>
  <subject>
    <topic>Antineoplastic agents</topic>
  </subject>
  <subject>
    <topic>Cancer</topic>
  </subject>
  <subject>
    <topic>Drugs</topic>
    <topic>Administration</topic>
  </subject>
  <subject>
    <topic>Pharmacognosy</topic>
  </subject>
  <subject authority="bisacsh">
    <topic>SCIENCE</topic>
    <topic>Life Sciences</topic>
    <topic>Biochemistry</topic>
  </subject>
  <subject authority="fast">
    <topic>Antineoplastic agents</topic>
  </subject>
  <subject authority="fast">
    <topic>Drugs</topic>
    <topic>Synthesis</topic>
  </subject>
  <classification authority="lcc">RS431.A64</classification>
  <classification authority="ddc" edition="23">615.7/98</classification>
  <classification authority="bisacsh">SCI007000</classification>
  <relatedItem type="otherFormat" displayLabel="Print version:">
    <titleInfo>
      <title>Antineoplastic drugs</title>
    </titleInfo>
    <name>
      <namePart>Lednicer, Daniel, 1929-</namePart>
    </name>
    <originInfo>
      <publisher>Chichester, West Sussex : Wiley, 2015</publisher>
    </originInfo>
    <identifier type="local">(DLC)  2015008084</identifier>
  </relatedItem>
  <identifier type="isbn">9781118892565</identifier>
  <identifier type="isbn">1118892569</identifier>
  <identifier type="isbn">9781118892558</identifier>
  <identifier type="isbn">1118892550</identifier>
  <identifier type="isbn">9781118892572</identifier>
  <identifier type="isbn">1118892577</identifier>
  <identifier type="isbn">1118892542</identifier>
  <identifier type="isbn">9781118892541</identifier>
  <identifier type="isbn" invalid="yes"/>
  <identifier type="lccn">2015014108</identifier>
  <identifier type="uri">http://onlinelibrary.wiley.com/book/10.1002/9781118892572</identifier>
  <location>
    <url>http://onlinelibrary.wiley.com/book/10.1002/9781118892572</url>
  </location>
  <recordInfo>
    <recordContentSource authority="marcorg">DLC</recordContentSource>
    <recordCreationDate encoding="marc">150408</recordCreationDate>
    <recordChangeDate encoding="iso8601">20171025091848.0</recordChangeDate>
    <recordIdentifier source="OCoLC">ocn904959309</recordIdentifier>
    <languageOfCataloging>
      <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
    </languageOfCataloging>
  </recordInfo>
</mods>
